ATE545023T1 - Verfahren zur vorhersage der fähigkeit einer zearalenon-analogverbindung für die krebsbehandlung - Google Patents
Verfahren zur vorhersage der fähigkeit einer zearalenon-analogverbindung für die krebsbehandlungInfo
- Publication number
- ATE545023T1 ATE545023T1 AT08845473T AT08845473T ATE545023T1 AT E545023 T1 ATE545023 T1 AT E545023T1 AT 08845473 T AT08845473 T AT 08845473T AT 08845473 T AT08845473 T AT 08845473T AT E545023 T1 ATE545023 T1 AT E545023T1
- Authority
- AT
- Austria
- Prior art keywords
- ability
- analog compound
- zearalenone analog
- cancer
- subject
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79607P | 2007-10-29 | 2007-10-29 | |
| PCT/US2008/081646 WO2009058908A2 (en) | 2007-10-29 | 2008-10-29 | Methods for prognosing the ability of a zearalenone analog compound to treat cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE545023T1 true ATE545023T1 (de) | 2012-02-15 |
Family
ID=40265002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08845473T ATE545023T1 (de) | 2007-10-29 | 2008-10-29 | Verfahren zur vorhersage der fähigkeit einer zearalenon-analogverbindung für die krebsbehandlung |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20090170925A1 (de) |
| EP (2) | EP2215471B1 (de) |
| JP (3) | JP5564431B2 (de) |
| AT (1) | ATE545023T1 (de) |
| AU (1) | AU2008318690B2 (de) |
| CA (1) | CA2704048A1 (de) |
| WO (1) | WO2009058908A2 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2670423T3 (es) | 2007-07-25 | 2018-05-30 | Eisai R&D Management Co., Ltd. | Inhibidores de multicinasas para uso en el tratamiento de cáncer |
| MA40354A (fr) * | 2014-07-18 | 2017-05-24 | Sanofi Sa | Procédé permettant de prédire le résultat d'un traitement avec de l'aflibercept d'un patient suspecté de souffrir d'un cancer |
| GB201602305D0 (en) * | 2016-02-09 | 2016-03-23 | Medical Res Council And Imp Innovations Ltd | TB Biomarkers |
| CN110684754B (zh) * | 2019-10-25 | 2021-11-23 | 江南大学 | 一种真菌毒素zen降解酶突变体及其应用 |
| CN110669745B (zh) * | 2019-10-25 | 2021-11-23 | 江南大学 | 一种热稳定性提高的玉米赤霉烯酮降解酶突变体及其应用 |
| CN115154460A (zh) * | 2022-08-10 | 2022-10-11 | 浙江大学 | 大环类化合物在制备治疗血液瘤药物中的应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB323845A (en) | 1928-10-30 | 1930-01-16 | John Thomas Hay | Corrosion resistant ferrous alloy |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4868103A (en) | 1986-02-19 | 1989-09-19 | Enzo Biochem, Inc. | Analyte detection by means of energy transfer |
| US4843155A (en) | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
| DE69326967T2 (de) | 1992-01-17 | 2000-06-15 | Lakowicz Joseph R | Phasenmodulationsenergieübertragungsfluoroimmunassay |
| AU4281393A (en) | 1992-04-10 | 1993-11-18 | Dana-Farber Cancer Institute, Inc. | Activation-state-specific phosphoprotein immunodetection |
| GB9225396D0 (en) | 1992-12-04 | 1993-01-27 | Sandoz Ltd | Improvements in or relating to organic compounds |
| AU7408094A (en) | 1993-07-29 | 1995-02-28 | Cor Therapeutics, Inc. | Receptor function assays |
| JPH0840893A (ja) | 1993-08-31 | 1996-02-13 | Takeda Chem Ind Ltd | インターロイキン−１産生抑制剤 |
| DK0730740T3 (da) | 1993-11-23 | 1998-09-28 | Genentech Inc | Kinasereceptoraktiveringsassay |
| US5795910A (en) | 1994-10-28 | 1998-08-18 | Cor Therapeutics, Inc. | Method and compositions for inhibiting protein kinases |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| US6441140B1 (en) | 1998-09-04 | 2002-08-27 | Cell Signaling Technology, Inc. | Production of motif-specific and context-independent antibodies using peptide libraries as antigens |
| CA2356622A1 (en) | 1998-12-24 | 2000-07-06 | Novation Pharmaceuticals Inc. | Compounds which affect mrna stability and uses therefor |
| US7833698B2 (en) * | 2000-01-12 | 2010-11-16 | Ventana Medical Systems, Inc. | Method for determining the response to cancer therapy |
| JP4317913B2 (ja) * | 2000-04-14 | 2009-08-19 | ベンタナ・メデイカル・システムズ・インコーポレーテツド | Ａｋｔタンパク質発現の定量方法 |
| EP1289472A4 (de) | 2000-05-30 | 2004-09-08 | Advanced Res & Tech Inst | Zusammensetzungen und verfahren zur identifikation von stoffen die die pten-funktion und die pi-3 kinase-wege modulieren |
| US7071164B2 (en) * | 2001-08-16 | 2006-07-04 | Kimberly-Clark Worldwide, Inc. | Anti-cancer and wound healing compounds |
| ES2376422T3 (es) * | 2001-08-21 | 2012-03-13 | Ventana Medical Systems, Inc. | Método y ensayo de cuantificación para determinar el estado c-kit/scf/pakt. |
| CA2471114C (en) * | 2001-12-21 | 2012-03-20 | The Wellcome Trust | Mutant b-raf polypeptide and a use thereof in the diagnosis of cancer |
| US20040096855A1 (en) * | 2001-12-24 | 2004-05-20 | Michael Stratton | Genes |
| US7915306B2 (en) | 2002-03-08 | 2011-03-29 | Eisai Co., Ltd. | Macrocyclic compounds useful as pharmaceuticals |
| EP2308861B1 (de) * | 2002-03-08 | 2017-03-01 | Eisai R&D Management Co., Ltd. | Macrocyclische verbindungen verwendbar als arzneitmitteln |
| US6942987B2 (en) | 2002-05-15 | 2005-09-13 | Pharmacopeia Drug Discovery, Inc. | Methods for measuring kinase activity |
| PL1663978T3 (pl) * | 2003-07-23 | 2008-04-30 | Bayer Healthcare Llc | Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów |
| US20050214325A1 (en) * | 2004-03-26 | 2005-09-29 | Vvii Newco 2003, Inc. | Compositions and methods to increase the effect of a neurotoxin treatment |
| WO2005089443A2 (en) * | 2004-03-19 | 2005-09-29 | The Penn State Research Foundation | Combinatorial methods and compositions for treatment of melanoma |
| BRPI0509580A (pt) * | 2004-03-30 | 2007-11-27 | Pfizer Prod Inc | combinações de inibidores de transdução de sinal |
| BRPI0511065A (pt) * | 2004-06-04 | 2007-12-26 | Pfizer Prod Inc | método para tratar crescimento de célula anormal |
| EP1794137A4 (de) * | 2004-09-27 | 2009-12-02 | Kosan Biosciences Inc | Spezifische kinase-hemmer |
| US20060216288A1 (en) * | 2005-03-22 | 2006-09-28 | Amgen Inc | Combinations for the treatment of cancer |
| US7976852B2 (en) | 2005-04-26 | 2011-07-12 | Eisai R&D Management Co., Ltd. | Compositions and methods for cancer immunotherapy |
| US7812143B2 (en) * | 2006-03-31 | 2010-10-12 | Memorial Sloan-Kettering Cancer Center | Biomarkers for cancer treatment |
| ES2670423T3 (es) * | 2007-07-25 | 2018-05-30 | Eisai R&D Management Co., Ltd. | Inhibidores de multicinasas para uso en el tratamiento de cáncer |
-
2008
- 2008-10-29 EP EP08845473A patent/EP2215471B1/de active Active
- 2008-10-29 JP JP2010531332A patent/JP5564431B2/ja active Active
- 2008-10-29 EP EP12154122.1A patent/EP2453234B1/de active Active
- 2008-10-29 US US12/290,405 patent/US20090170925A1/en not_active Abandoned
- 2008-10-29 CA CA2704048A patent/CA2704048A1/en not_active Abandoned
- 2008-10-29 WO PCT/US2008/081646 patent/WO2009058908A2/en active Application Filing
- 2008-10-29 AU AU2008318690A patent/AU2008318690B2/en active Active
- 2008-10-29 AT AT08845473T patent/ATE545023T1/de active
-
2013
- 2013-11-28 JP JP2013246099A patent/JP2014042531A/ja not_active Withdrawn
-
2015
- 2015-12-04 JP JP2015237576A patent/JP2016034287A/ja active Pending
-
2016
- 2016-03-02 US US15/059,056 patent/US20160291027A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011502473A (ja) | 2011-01-27 |
| JP5564431B2 (ja) | 2014-07-30 |
| EP2215471A2 (de) | 2010-08-11 |
| AU2008318690B2 (en) | 2015-08-13 |
| EP2453234A3 (de) | 2012-08-29 |
| WO2009058908A3 (en) | 2009-10-22 |
| US20090170925A1 (en) | 2009-07-02 |
| EP2453234B1 (de) | 2014-01-15 |
| US20160291027A1 (en) | 2016-10-06 |
| EP2215471B1 (de) | 2012-02-08 |
| CA2704048A1 (en) | 2009-05-07 |
| JP2016034287A (ja) | 2016-03-17 |
| EP2453234A2 (de) | 2012-05-16 |
| WO2009058908A2 (en) | 2009-05-07 |
| AU2008318690A1 (en) | 2009-05-07 |
| JP2014042531A (ja) | 2014-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE545023T1 (de) | Verfahren zur vorhersage der fähigkeit einer zearalenon-analogverbindung für die krebsbehandlung | |
| ATE523786T1 (de) | In-vitro-verfahren zur prognose des fortschreitens einer krebserkrankung und des ausgangs für einen patienten sowie verfahren zur durchführung des verfahrens | |
| DE602006014843D1 (de) | Verwendung von hif 1alfa modulatoren zur behandlung von krebs | |
| ATE547102T1 (de) | Carbolin-derivate zur behandlung von krebs | |
| WO2009049214A3 (en) | Inhibition and treatment of prostate cancer metastasis | |
| DE602007006479D1 (de) | Verfahren und vorrichtungen zur behandlung von mehreren bohrlochintervallen | |
| BRPI0510177A (pt) | heterociclos monocìclicos como inibidores de cinase | |
| ATE552000T1 (de) | Verwendung von isothiocyanat-verbindungen zur behandlung von prostata-erkrankungen und hautkrebs | |
| TW200642695A (en) | Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs) | |
| DE602005011656D1 (de) | Verfahren zur behandlung von dickdarmkrebs mit botulinum neurotoxin | |
| DE602007001241D1 (de) | Vorrichtung zur Zuweisung von Unterkanälen und entsprechendes Verfahren | |
| WO2010042933A3 (en) | Inhibition and treatment of prostate cancer metastasis | |
| DE502005004218D1 (de) | Verfahren zur umesterung von fetten und ölen biologischen ursprungs mittels alkoholyse unter verwendung spezieller kohlensäuresalze | |
| DE602005017373D1 (de) | Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten | |
| WO2011091366A3 (en) | Methods of treating or preventing periodontitis and diseases associated with periodontitis | |
| EA201492284A1 (ru) | Применение маркеров в диагностике и лечении рака предстательной железы | |
| ATE540676T1 (de) | Egfr-inhibitoren zur behandlung und diagnose von metastasierendem prostatakrebs | |
| DE602006009899D1 (de) | Verwendung von oxycodon zur behandlung von viszeralem schmerz | |
| WO2013119950A3 (en) | Methods and compositions relating to fusions of ros1 for diagnosing and treating cancer | |
| BRPI0908635A8 (pt) | composto, composição farmacêutica e método de tratamento de câncer | |
| DE602006017367D1 (de) | Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut | |
| ATE507198T1 (de) | Mehrstufiges kontinuierliches verfahren zur hydroformylierung von höheren olefinen oder olefingemischen | |
| EA201791236A1 (ru) | Применение ингибиторов пан fgfr и способ идентификации пациентов, заболевших раком, для лечения с помощью ингибитора пан fgfr | |
| ATE516290T1 (de) | Verfahren zur herstellung von buprenorphin und derivaten von buprenorphin | |
| DE602005027251D1 (de) | Sulfamide alsendothelinrezeptorantagonsiten zur behandlung von herzkreislauferkrankungen |